Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Novo Nordisk's sharp 54% decline is driven ... will divert significant prescription volume to NVO's products. The CEO's resignation is a short-term destabilizing and unsettling development for ...

Global pressures and a leadership change Novo Nordisk's CEO, Lars Fruergaard Jørgensen ... market share against Wegovy and Ozempic. The resignation was described as a mutual decision between ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. I believe this is due to the strong performance of its GLP-1 products ...

Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will step down from his position. The decision can be attributed to increasing competitive pressure and recent market challenges ...

Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will step down from his position. The decision can be attributed to increasing competitive pressure and recent market challenges that ...

COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing ...

the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO) abruptly announced the resignation of veteran CEO Lars Fruergaard Jørgensenm last week. The stock has dropped by over 49% in the ...

On the 16th (local time), Novo Nordisk noted that Lars Fruer Jørgensen, Chief Executive Officer (CEO), will resign. He joined Novo Nordisk in 1991 and has led the company since 2017. Novo Nordisk ...